Search results
Despite the knock-on effects of the pandemic, there’s been a lot going on this year in the world of research! Here are snapshots of a few stories that have appeared in the Research News section of our website in 2022.
The aim of the site is to increase the level of awareness and understanding of genetic testing and genetic counselling among people living with inherited retinal dystrophies, empowering them to make fully informed decisions about their lives, healthcare and family planning.
Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
Thursday 16 July 2026, 7.00pm - 8.00pm - via Zoom - Please come and join us for our Summer meeting where we are delighted to welcome our guest speakers Bhavini Makwana and Eamonn Dunne, Policy & Campaigns Managers at Thomas Pocklington Trust.
Saturday 12 September 2026, 11.00am - 4.00pm - In-person - Please come and join Scotland group facilitator, Sarah Speed for a fabulous day out in Falkirk, visiting the Kelpies at Helix park followed by lunch at Italian restaurant, Gambero Rosso.
Monday 7 September 2026, 7pm - 8pm - via Zoom - Please come and join facilitator James Birtley and the Berkshire group for their latest online social catch up.
Saturday 8 August 2026, 12.30pm - 6.30pm - In-person - Please come and join Rachael and the group at The Waldorf pub in Manchester for their latest social get together including guest speakers Katy Whitwell & Lisa Howell from the RNIB's ECLO service.
Have you ever been tempted to take part in the TCS London Marathon? In 2022 the TCS London Marathon raised £58.3 million for charity so it’s a vital source of income.
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
